Independent Research
ORKA Analysis
3 pieces of research on Oruka Therapeutics, Inc.. We find the signal management buried in the earnings call.
0signal analyses
3news briefs
latest: Jun 2, 2026
News Briefs (3)
News Brief
Oruka Therapeutics Expands IL-23 Drug Rights But Delays Key IBD Trial
Oruka Therapeutics widened its IL-23 indication rights but delayed IBD dosing timelines, removing a near-term catalyst while Piper Sandler held its Overweight r…
Read analysis →News Brief
Oruka Therapeutics Raises $700M at $72.50 After 64% Skin-Clearance Readout
Oruka Therapeutics priced an upsized $700M stock offering at $72.50 after Phase 2a data showed 64% of psoriasis patients achieved clear skin, with UBS raising i…
Read analysis →News Brief
Oruka Therapeutics Stock Hits Record High on Psoriasis Drug Data, Then Launches $500M Offering
Oruka Therapeutics surged to a record high after Phase IIa data showed 64% skin clearance for its once-yearly psoriasis drug, then launched a $500M public offer…
Read analysis →